The two companies hope that the partnership will secure the future of the ingredient as a dominant force in the joint health category. Under the agreement Stratum Nutrition, the human nutrition division of Novus International, will help ESM advance the science behind NEM and support marketing and sales efforts.
“We evaluated several other technologies in the joint health category, but chose NEM because we feel it has the best potential to become the next dominant joint health ingredient,” said Jeremy Moore, Marketing director for Stratum Nutrition.
Moore cited some of the key factors that persuaded Stratum to invest in NEM instead of other joint health ingredients. He said NEM has a small daily dose size (500 mg), a robust yet safe supply chain, and clinically proven results in osteoarthritic patients within 7-10 days. NEM also has good sustainability credentials, according to ESM and Stratum.
“By utilizing a portion of the egg that has historically been discarded by suppliers of liquid eggs (the shell and membrane), we are reducing the amount of these materials that would normally go to waste and be sent to either a landfill or spread on fields,” said Micah Osborne, ESM president.